PolyPeptide Group AG and its billionaire shareholder Frederik Paulsen are working on strategic options for the company.
The Swiss contract drugmaker’s review is at an early stage and “there can be no assurances” that it will result in any transaction or other outcome, the company said in a statement on Tuesday. PolyPeptide said it is “well positioned” to achieve its ambition to double 2023 revenue by 2028.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.